Clinical Trials Browser

Phase 2 × Carcinoma in Situ × Genitourinary × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04387461 2024-09-25

CORE-001

Phase 2 Completed

35 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2 Terminated

17 enrolled 9 charts

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Phase 2 Completed

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00141531 2012-06-14

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Phase 2 Completed

53 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

ADVANCED-2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

OHAI-NMIBC-01

CORE-001

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer